Table 3.
Effect of inter-person differences and within-person changes in TRAb levels on clinical characteristics: longitudinal associations during a 1-year follow-up
| Variables | Effect of TSI on clinical characteristics | |
| Estimated change (SE) | P value* | |
| CAS | ||
| Inter-person | 0.0013 (0.0007) | 0.0731 |
| Within-person | 0.0011 (0.0008) | 0.1510 |
| NOSPECS | ||
| Inter-person | 0.0043 (0.0013) | 0.0013 |
| Within-person | 0.0002 (0.0007) | 0.7700 |
| Proptosis | ||
| Inter-person | 0.0032 (0.0022) | 0.1410 |
| Within-person | −0.0010 (0.0007) | 0.1796 |
| Variables | Effect of TBII on clinical characteristics | |
| Estimated change (SE) | P value* | |
| CAS | ||
| Inter-person | 0.0392 (0.0109) | 0.0004 |
| Within-person | 0.0261 (0.0173) | 0.1334 |
| NOSPECS | ||
| Inter-person | 0.0520 (0.0242) | 0.0335 |
| Within-person | 0.0249 (0.0152) | 0.1036 |
| Proptosis | ||
| Inter-person | 0.0775 (0.0379) | 0.0428 |
| Within-person | 0.0017 (0.0167) | 0.3095 |
*P values were calculated using a linear mixed model with time-dependent covariates adjusted for age, sex, smoking status and treatment modality. Numbers in bold denote statistically significant changes.
CAS, clinical activity score; NOSPECS, no signs or symptoms, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, sight loss; TBII, thyroid-stimulating hormone receptor-binding inhibitory immunoglobulin; TRAb, thyroid-stimulating hormone receptor antibody; TSI, thyroid-stimulating immunoglobulin.